(Q34627751)

3 August 2017

Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice (English)

1 reference

3 August 2017

8

Naftali Kaminski

1 reference

3 August 2017

Laura P Stabile

1

1 reference

3 August 2017

Mary E Rothstein

2

1 reference

3 August 2017

Phouthone Keohavong

3

1 reference

3 August 2017

Diana Lenzner

4

1 reference

3 August 2017

Stephanie R Land

5

1 reference

3 August 2017

Autumn L Gaither-Davis

6

1 reference

3 August 2017

K Jin Kim

7

1 reference

3 August 2017

Jill M Siegfried

9

1 reference

3 August 2017

1 December 2010

1 reference

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

2153-2170

1 reference

3 August 2017

4

1 reference

Creative Commons Attribution 4.0 International

3 August 2017

start time

22 December 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

describes a project that uses

ImageQuant

object named as

ImageQuant

2 references

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC3049550/fullTextXML

based on heuristic

inferred from PubMed Central ID database lookup

CZ Software Mentions: A large dataset of software mentions in the biomedical literature

cites work

Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

EGFRvIII and c-Met pathway inhibitors synergize against PTEN-null/EGFRvIII+ glioblastoma xenografts.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

KRAS mutations in non-small cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

MET as a target for treatment of chest tumors

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Signaling networks assembled by oncogenic EGFR and c-Met

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Ras effector pathways modulate scatter factor-stimulated NF-kappaB signaling and protection against DNA damage

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Evidence for autocrine actions of neuromedin B and gastrin-releasing peptide in non-small cell lung cancer

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3049550

Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.

7 July 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS2042153

Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS2042153

Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS2042153

Impact of serum hepatocyte growth factor on treatment response to epidermal growth factor receptor tyrosine kinase inhibitors in patients with non-small cell lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS2042153

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS2042153

Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS2042153

MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.3390%2FCANCERS2042153

Serum hepatocyte growth factor as a marker of tumor activity in head and neck squamous cell carcinoma

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21390244

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21390244

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.3390/CANCERS2042153

1 reference

3 August 2017

1 reference

3 August 2017

1 reference